Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

Table 5 Univariate and multivariate analysis of clinicopathological factors associated with DFS

Variables	5-year DFS rate (%)	Univariate P-value	Multivariate analysis
Variables	5-year DFS rate (%)	Univariate P-value	HR (95% CI)	P-value
< Patient’s factor >
Age (< 70 years / ≥70 years)	64.3/71.2	0.35
Sex (men/women)	70.7/58.6	0.24
< Pre-CRT factor >
Stage (I,II/III)	68.6/65.9	0.53
Main tumor location (Ra/Rb, P)	83.3/64.5	0.28
< Treatment factor >
Drug (S-1/UFT)^a	67.8 / 68.8	0.72
Surgical procedure (LAR/ others)	79.8 / 56.5	0.03	2.95 (1.32–6.59	0.009
< Post-CRT factor >
Tumor differentiation (diff./undiff.)	67.9/57.1	0.69
fStage (I, II/III)	79.0/44.7	< 0.0001	2.64 (1.23–5.68)	0.01
T (1,2/3,4)	77.0/60.6	0.12
Lymph node metastasis (−/+)^b	78.3/42.9	0.0001
Venous invasion (−/+)	70.8/63.1	0.24
Lymphatic invasion (−/+)	77.6/40.0	< 0.0001	4.07 (1.86–8.91)	0.0005
IDO (−: +)	69.0/62.6	0.53
PD-L1 (−: +)	69.4/64.4	0.49
Pathological response (Non-responder /Responder)	74.5/62.8	0.13

DFS Disease-free survival, CRT Chemoradiotherapy, Ra Upper rectum, Rb Lower rectum, P Anal canal, diff./undiff. Differentiated histological type/undifferentiated histological type, IDO Indoleamine-pyrrole 2,3-dioxygenase, PD-L1 Programmed death-ligand 1, fStage Final pathological stage, HR Hazard ratio, CI Confidence interval
^aOne patient who used 5-FU for CRT was excluded
^bLymph node metastasis was excluded from multivariate analysis because it was confounder of fStage

ISSN: 1471-2407